Nifin10 mg

Nifin is a dihydropyridine calcium channel blocker used for the following indications:

Established / FDA-approved uses

• Hypertension (extended-release formulation only) — used alone or in combination with other antihypertensive agents to lower blood pressure.
• Chronic stable angina (effort-associated angina) — both immediate-release and extended-release formulations of Nifin are approved for management of chronic stable angina.
• Vasospastic angina (Prinzmetal's or variant angina) — immediate-release Nifin capsules are approved for confirmed or suspected vasospastic angina.

Guideline-supported off-label uses

• Tocolysis for preterm labor — Nifin is commonly used off-label, and is supported by obstetric guidelines, as a tocolytic to delay preterm delivery for a short period (typically up to about 48 hours) to allow administration of antenatal corticosteroids or transfer to a facility with neonatal intensive care.
• Raynaud phenomenon — Nifin is used off-label to reduce the frequency and severity of vasospastic episodes.
• Prevention of high-altitude pulmonary edema (HAPE) in susceptible individuals — Nifin is used off-label for high-risk mountaineers.

Note: Immediate-release Nifin capsules are not indicated, and should not be used, for treatment of hypertension or hypertensive emergencies (see Precautions and Warnings).

Each Nifedipine immediate-release capsule or extended-release tablet contains Nifedipine as the active ingredient. Commonly marketed strengths include 5 mg and 10 mg immediate-release capsules, and 20 mg, 30 mg, and 60 mg extended-release tablets, together with standard pharmaceutical excipients required for the immediate- or sustained-release formulation.

Nifin is a dihydropyridine derivative calcium channel blocker (calcium antagonist) that relaxes vascular smooth muscle and dilates coronary and peripheral arteries. It is used in the long-term management of hypertension and angina pectoris. Nifin is available as an immediate-release capsule and as extended/sustained-release tablets; these formulations have different indications, dosing, and safety profiles and are not interchangeable.

Nifin belongs to the dihydropyridine class of calcium channel blockers (CCBs), a subgroup of antihypertensive and antianginal agents.

Nifedipine inhibits the influx of calcium ions through L-type voltage-gated calcium channels in vascular smooth muscle and, to a lesser extent, cardiac muscle. This relaxes coronary and peripheral arterial smooth muscle, decreasing peripheral vascular resistance and blood pressure, and dilating coronary arteries to improve myocardial oxygen supply. Compared with non-dihydropyridine calcium channel blockers, Nifedipine has minimal direct effect on cardiac conduction (SA/AV node) or contractility at therapeutic doses, though reflex sympathetic activation (tachycardia) can occur, particularly with the immediate-release formulation. Nifedipine is extensively metabolized in the liver via the CYP3A4 enzyme pathway to inactive metabolites and is primarily excreted in urine.

Swallow extended-release Nifin tablets whole with a full glass of water; do not crush, chew, break, or split them, as this destroys the controlled-release mechanism. Nifin may be taken with or without food, but grapefruit and grapefruit juice should be avoided (see Interaction). Take Nifin at the same time each day and do not stop it abruptly without consulting a physician.

• Grapefruit / grapefruit juice: significantly increases Nifin blood levels by inhibiting intestinal CYP3A4 metabolism, raising the risk of hypotension and other adverse effects; avoid concurrent consumption.
• Strong CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, clarithromycin, ritonavir): increase Nifin plasma concentration and the risk of hypotension; use with caution or avoid.
• Strong CYP3A4 inducers (e.g. rifampin, carbamazepine, phenytoin): reduce Nifin plasma concentration and may reduce efficacy.
• Other antihypertensives, nitrates, or alcohol: additive blood-pressure–lowering and hypotensive effect when combined with Nifin.
• Digoxin: Nifin may modestly increase digoxin plasma levels; monitor for digoxin toxicity.
• Magnesium sulfate (used in obstetric settings): concurrent use with Nifin may cause profound hypotension and neuromuscular blockade; combine only under close specialist monitoring.

Common

• Peripheral edema (swelling of the ankles/feet) — the most common dose-dependent side effect of Nifin.
• Headache
• Flushing and a sensation of warmth
• Dizziness or light-headedness
• Reflex tachycardia or palpitations (more common with immediate-release Nifin)

Less common

• Constipation
• Nausea
• Gingival hyperplasia (gum overgrowth) with prolonged use
• Fatigue or weakness

Seek prompt medical attention for signs of a serious reaction, such as chest pain, fainting, marked swelling, or difficulty breathing, while taking Nifin.

Pregnancy: Nifin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and only under the guidance of a physician. Despite this cautious labeling position, Nifin is widely used off-label in obstetric practice (for example, for preterm labor tocolysis and blood-pressure control in severe pre-eclampsia) under specialist supervision. Do not use Nifin in pregnancy without consulting a physician.

Lactation: Nifin is excreted into breast milk in small amounts. It should be used during breastfeeding only if clearly needed, with the infant monitored for potential effects, and only on the advice of a physician.

Immediate-release vs. extended-release — do not interchange

Immediate-release and extended-release Nifin formulations differ substantially in dosing, release profile, and safety profile and must never be substituted for one another. Immediate-release Nifin capsules, because of their rapid onset and potential to cause a sharp fall in blood pressure with reflex tachycardia, should be avoided in patients with acute myocardial infarction or unstable angina — a well-documented historical safety concern that led to a shift in clinical practice toward exclusive use of extended-release Nifin for hypertension.

Severe aortic stenosis

Use Nifin with caution in patients with severe aortic stenosis, as vasodilation in the presence of a fixed outflow obstruction can precipitate significant hypotension.

Hepatic impairment

Nifin is extensively metabolized by the liver; use with caution and consider a lower starting dose in patients with hepatic impairment.

Grapefruit

Avoid grapefruit and grapefruit juice while taking Nifin (see Interaction).

Do not stop abruptly

Do not discontinue Nifin suddenly without medical advice, as abrupt discontinuation may worsen angina in some patients.

Hypotension

Monitor blood pressure, particularly at initiation or dose increase of Nifin, since symptomatic hypotension can occur, especially in patients also taking other antihypertensive drugs.

Overdose of Nifin can cause pronounced and prolonged hypotension, bradycardia or reflex tachycardia, cardiac conduction disturbances, loss of consciousness, and metabolic disturbances such as hyperglycemia. Overdose of Nifin is a medical emergency — seek immediate medical attention or contact a poison control center/emergency services right away. Do not attempt to manage a suspected Nifin overdose at home; treatment requires close hemodynamic monitoring and supportive care in a medical facility.

Store Nifin at room temperature (below 30°C), protected from light and moisture, in its original container. Keep out of reach of children.

• Elderly: more sensitive to the blood-pressure–lowering effects of Nifin; initiate at the lower end of the dosing range and monitor closely.
• Hepatic impairment: reduced clearance of Nifin; use a lower starting dose (see Precautions and Warnings).
• Renal impairment: no specific dose adjustment generally required for Nifin, but monitor blood pressure and renal function.
• Pediatric patients: safety and efficacy of Nifin have not been established for routine pediatric use (see Pediatric Uses).
• Pregnancy and breastfeeding: see Pregnancy and Lactation.

For hypertension and chronic stable angina, Nifin is typically used long-term/continuously as directed by a physician, with periodic reassessment. For off-label tocolysis in preterm labor, Nifin is generally used short-term (up to approximately 48 hours) under obstetric supervision.

Calcium channel blockers (dihydropyridine subclass); antihypertensive and antianginal agent.

Nifedipine blocks L-type calcium channels in vascular smooth muscle, reducing calcium influx and causing arterial vasodilation. This lowers systemic vascular resistance and blood pressure, and dilates coronary arteries to increase myocardial oxygen supply, with minimal direct effect on cardiac conduction at therapeutic doses.

C

Safety and efficacy of Nifin have not been formally established in children for routine treatment of hypertension. Nifin is used off-label in some pediatric hypertensive settings under specialist (pediatric cardiology/nephrology) supervision, with weight-based dosing individualized by the treating specialist; it should not be used in children outside specialist guidance.